Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Arcus Biosciences Inc. (RCUS:NYSE), powered by AI.
Arcus Biosciences Inc. is currently trading at $23.80. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Arcus Biosciences Inc. on Alpha Lenz.
View Arcus Biosciences Inc.'s valuation metrics on Alpha Lenz.
“Arcus Biosciences Inc.'s ROE is -63.3%. Explore profitability and growth together.”
Ask for details →Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. One of its core strategies is to develop next-generation treatments that can potentially improve upon existing therapies, enhancing efficacy while minimizing side effects. Operating in an industry marked by rapid scientific advancements, Arcus Biosciences plays a critical role in the ongoing pursuit of more effective cancer treatments. Its efforts contribute to the diversification of therapeutic options available to clinicians, offering hope to patients managing the challenges of cancer. Through strategic partnerships and robust research initiatives, Arcus Biosciences continues to expand its impact within the highly competitive biopharmaceutical sector, underscoring the importance of innovation in the battle against cancer.
“Arcus Biosciences Inc.'s ROE is -63.3%. Explore profitability and growth together.”
Ask for details →Arcus Biosciences Inc. (ticker: RCUS) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 627 employees.
The current price is $23.8 with a P/E ratio of -x and P/B of -x.
ROE is -63.26% and operating margin is -156.28%. Annual revenue is $247M.